

Accepted Manuscript

Title: Immunomodulatory effects of CD38-targeting antibodies

Author: Niels W.C.J. van de Donk

PII: S0165-2478(18)30147-0
DOI: <https://doi.org/10.1016/j.imlet.2018.04.005>
Reference: IMLET 6200

To appear in: *Immunology Letters*

Received date: 21-3-2018

Accepted date: 23-4-2018



Please cite this article as: van de Donk Niels W.C.J. Immunomodulatory effects of CD38-targeting antibodies. *Immunology Letters* <https://doi.org/10.1016/j.imlet.2018.04.005>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Immunomodulatory effects of CD38-targeting antibodies

Niels W.C.J. van de Donk¹

¹Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands

Running title: Immunomodulatory activity of CD38 antibodies

Corresponding author: Dr. Niels W.C.J. van de Donk, MD, PhD

Department of Hematology

VU University Medical Center

De Boelelaan 1117

1081HV Amsterdam

The Netherlands

Email: n.vandedonk@vumc.nl

Tel: +31 (0)20 4442604

Fax: +31 (0)20 44442601

HIGHLIGHTS

- -CD38-targeting antibodies have classic Fc-dependent immune effector mechanisms
- -CD38-targeting antibodies also have novel immunomodulatory activity
- -CD38-targeting antibodies synergize with other immune stimulating agents

Abstract word count: 188

Number of figures: 2

Number of tables: 0

Number of references: 80

ABSTRACT

The first in class CD38-targeting antibody, daratumumab, is currently approved as single agent and in combination with standards of care for the treatment of relapsed and refractory multiple myeloma. Based on the high activity and favorable toxicity profile of daratumumab, other CD38 antibodies, such as isatuximab, MOR202, and TAK-079, are being evaluated in

Download English Version:

<https://daneshyari.com/en/article/8738294>

Download Persian Version:

<https://daneshyari.com/article/8738294>

[Daneshyari.com](https://daneshyari.com)